2020年5月19日

研究人員正在研究COVID-19疫苗以應對可能的冠狀病毒突變-報告©路透社/ Dado Ruvic https://sputniknews.com/world/202005191079354001-researchers-are-working-on-covid-19-vaccine-to-address-possible-coronavirus-mutations-report/來自世界各地的科學家目前正在開發針對SARS-CoV-2的疫苗，目前正在測試一些現有藥物治療COVID-19患者的能力。據《海峽時報》報道，新加坡Esco Aster公司的研究人員目前正與美國Vivaldi生物科學公司合作開發一種疫苗，這種疫苗不僅能治療冠狀病毒，還能在三周內進行修改，以應對病毒的任何可能突變。報道指出，這種即將問世的疫苗目前被命名為Esco Aster DeltaCov，是通過來自流感病毒的“骨幹”蛋白和來自SARS-CoV-2的抗原合並而成，旨在刺激免疫反應。人體試驗預計將在六個月內開始。易思達首席執行官林向良向《海峽時報》解釋說:“病毒實際上想要潛伏起來，不被識別——它們想要避開免疫係統，不引起任何反應。”“有了這樣的骨氣……我們可以喚醒免疫係統，讓它意識到有一種新型病毒，並製造出殺死它所需的抗體。”據報道，在新加坡記錄到第一例冠狀病毒病例後，Esco Aster於2020年1月聯係了Vivaldi生物科學公司。該公司開始尋找“正確的抗原序列”，試圖將其插入到主幹中，而Vivaldi生物科學公司則對病毒進行基因逆向工程，以便將其抗原與蛋白質主幹連接起來。根據科學家的說法，如果新冠病毒發生突變，必須開發一種新疫苗，那麼這些過程將被使用。 In this case, the new drug for the “mutated” virus would thus emerge as early as in two weeks, as the new virus strain will simply be “switched” with the current antigens. The upcoming vaccine will be produced in the form of a nasal spray, according to the company, and testing on animals is expected to begin in two or three months. Once the inserted coronavirus antigen is detected by the organisms’ immune system, the body will learn to detect the virus and produce antibodies to fight it in the future. Another US-based biopharmaceutical company, Sorrento Therapeutics, had earlier said that so-called “antibody cocktail therapy” could soon be applied to protect American citizens returning to the workplace amid the absence of a currently approved vaccine against coronavirus, as scientists from all over the world, including Russia, China and the UK, are working on the development of an anti-COVID-19 vaccine, with testing expected to begin as early as this June. ...